Wall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High?
AlloVir, Inc. (ALVR) closed the last trading session at $7.65, gaining 9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...
AlloVir, Inc. (ALVR) closed the last trading session at $7.83, gaining 45.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...
Insiders at AlloVir, Inc. (NASDAQ:ALVR) sold US$11m worth of stock at an average price of US$28.92 a share over the past year, making the most of their investment. The company's market valuation ...
SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired AlloVir, Inc. (NASDAQ: ALVR ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AlloVir, Inc. (NASDAQ: ALVR) and Kalaris Therapeutics is fair to AlloVir shareholders.
B of A Securities analyst Jason Zemansky initiated coverage on AlloVir Inc ALVR with a Buy rating and announced a price target of $17. AlloVir is a clinical-stage biotech advancing cell therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results